Treatment of Rhino-orbital-cerebral Mucormycosis in Pre-existing Renal Compromise or Renal Failure
Rhino-orbital-cerebral mucormycosis (ROCM) demands urgent, coordinated management. In patients with pre-existing renal compromise or renal failure, the choice of systemic antifungal therapy requires specific adaptation — renal status directly determines which agents are appropriate.
Clinical scenario: ROCM arising in a patient with pre-existing renal compromise or renal failure. Renal impairment is a critical factor when selecting antifungal therapy, as agents with significant nephrotoxic potential must be avoided to protect remaining kidney function.
Treatment approach — partial overview
First-line management combines early complete surgical debridement — performed whenever feasible and repeated as required — with immediate systemic antifungal therapy specifically selected to avoid agents harmful to the kidneys. Treatment response is assessed at regular intervals (e.g., weekly imaging), with the clinical target being at least stable disease or partial response.
The full structured regimen — including specific agent selection, intravenous versus oral sequencing, and step-down criteria — is available via the complete protocol.
References
- In case of renal failure, posaconazole or isavuconazole were shown to be effective.
- The guideline group strongly supports an early complete surgical treatment for mucormycosis whenever possible, in addition to systemic antifungal treatment.
- Isavuconazole is recommended with moderate strength for the first-line treatment of mucormycosis.
- The group marginally supports use of posaconazole oral suspension, and moderately supports posaconazole delayed release tablets and infusion for first-line treatment.
- When switching to oral treatment, use of isavuconazole or posaconazole delayed release tablets is strongly supported.
- There is moderate support for intravenous treatment until stable disease is achieved.
View source ↗